Study to Evaluate Nosocomial Transmission of Influenza

Pilot Study to Develop a Model to Evaluate Nosocomial Transmission of Influenza

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00798421

Enrollment

Registered

2008-11-26

Start date

2008-12-31

Completion date

2009-05-31

Last updated

2008-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Influenza, transmission

Brief summary

The purpose of this study is to investigate whether influenza can be reliably transmitted from children to susceptible contacts in a health care setting. The goal is to develop a transmission that can then be used to assess interventions to prevent transmission Research objectives: To develop a model to investigate the frequency of influenza transmission from an infected child to a susceptible health care worker Research Hypotheses: Influenza viruses can be transmitted from infected children to exposed health care workers

Detailed description

CHildren with influenza infection presenting to ED will be identified by RAT. Healthy healthcare worker subjects will expose themselves and perform specific activities with the child. subjects will be followed by diary card, clinical symptom scores and virology swabs to assess frequency of transmission

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Infected Children * Age \< 16 years * Parents or legal guardians willing to give informed written consent * Presenting with a febrile illness confirmed as influenza by near patient rapid antigen testing * Healthy volunteers * Willing to give informed written consent

Exclusion criteria

* Children * No parents or legal guardians able to give informed consent * Healthy volunteers * known allergy to oseltamivir or zanamivir * presence of underlying condition or concomitant therapy requiring dose alteration of oseltamivir (severe renal or hepatic failure; methotrexate and probenecid) * underlying immunosuppressive disorder * known galactose intolerance * underlying chronic medical condition known to increase risk of influenza-related complications (including asthma, chronic pulmonary airways disease, chronic cardiovascular disease, diabetes mellitus, chronic neurological disorder) * inability or contraindication to collection of nasal swabs * previous influenza vaccination within 2 years * current smoker * pregnancy

Design outcomes

Primary

Measure	Time frame
Frequency of transmission of influenza	1 weeks

Countries

United Kingdom

Contacts

Primary ContactIain Stephenson, FRCP

iain.stephenson@uhl-tr.nhs.uk+44 116 258 6952

Outcome results